Log in

NASDAQ:TLCTAIWAN LIPOSOME/S Stock Price, Forecast & News

$4.91
-0.17 (-3.35 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.90
Now: $4.91
$4.93
50-Day Range
$3.70
MA: $4.64
$5.50
52-Week Range
$2.48
Now: $4.91
$8.54
Volume1,637 shs
Average Volume2,545 shs
Market Capitalization$182.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.44
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site. The company provides various product candidates that target various areas of unmet medical need in pain management, ophthalmology, and oncology. Its lead product candidate is TLC599, is an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP) that is in Phase II clinical trials for knee osteoarthritis pain. The company's product candidates also comprises TLC399, BioSeizer formulation of DSP intended as an intravitreal injection for the treatment of macular edema due to retinal vein occlusion; TLC590, a non-opioid anesthetic for post-surgical pain management; and TLC178, an API to treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei City, Taiwan with offices in Hsinchu, Hong Kong, Leiden, Melbourne, Shanghai, South San Francisco, and Tokyo.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TLC
CUSIPN/A
CIKN/A
Phone886-2-2655-7377

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.99 million
Book Value$0.65 per share

Profitability

Net Income$-27,000,000.00
Net Margins-1,321.75%

Miscellaneous

EmployeesN/A
Market Cap$182.16 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive TLC News and Ratings via Email

Sign-up to receive the latest news and ratings for TLC and its competitors with MarketBeat's FREE daily newsletter.

TAIWAN LIPOSOME/S (NASDAQ:TLC) Frequently Asked Questions

How has TAIWAN LIPOSOME/S's stock been impacted by COVID-19 (Coronavirus)?

TAIWAN LIPOSOME/S's stock was trading at $3.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TLC stock has increased by 27.5% and is now trading at $4.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TAIWAN LIPOSOME/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TAIWAN LIPOSOME/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TAIWAN LIPOSOME/S.

When is TAIWAN LIPOSOME/S's next earnings date?

TAIWAN LIPOSOME/S is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for TAIWAN LIPOSOME/S.

How were TAIWAN LIPOSOME/S's earnings last quarter?

TAIWAN LIPOSOME/S (NASDAQ:TLC) announced its earnings results on Wednesday, May, 8th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.19. The company earned $5.11 million during the quarter, compared to analysts' expectations of $3 million. TAIWAN LIPOSOME/S had a negative net margin of 1,321.75% and a negative return on equity of 158.55%. View TAIWAN LIPOSOME/S's earnings history.

What price target have analysts set for TLC?

3 Wall Street analysts have issued twelve-month price objectives for TAIWAN LIPOSOME/S's shares. Their forecasts range from $10.00 to $11.00. On average, they expect TAIWAN LIPOSOME/S's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 113.8% from the stock's current price. View analysts' price targets for TAIWAN LIPOSOME/S.

Has TAIWAN LIPOSOME/S been receiving favorable news coverage?

News stories about TLC stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. TAIWAN LIPOSOME/S earned a news impact score of -1.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutTAIWAN LIPOSOME/S.

Who are some of TAIWAN LIPOSOME/S's key competitors?

What other stocks do shareholders of TAIWAN LIPOSOME/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TAIWAN LIPOSOME/S investors own include Gilead Sciences (GILD), Wells Fargo & Co (WFC), IBM (IBM), Pfizer (PFE), AbbVie (ABBV), Applied Genetic Technologies (AGTC), Franklin Resources (BEN), Bank of Nova Scotia (BNS), Canadian Natural Resources (CNQ) and Enbridge (ENB).

Who are TAIWAN LIPOSOME/S's key executives?

TAIWAN LIPOSOME/S's management team includes the following people:
  • Dr. Keelung Hong, Founder, Chairman & CEO (Age 75)
  • Mr. Zhi-Hong Yeh M.B.A., Pres & GM (Age 46)
  • Ms. Ru-Yun Lin M.B.A., CFO and VP of Fin. & Admin. (Age 53)
  • Dr. Wenji Chen M.B.A., Ph.D., VP of Corp. Devel. Division (Age 59)
  • Dr. Luke Guo Ph.D., Chief Scientific Advisor & Member of Scientific Advisory Board

When did TAIWAN LIPOSOME/S IPO?

(TLC) raised $29 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 5,000,000 shares at $5.80 per share. Cantor served as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers.

What is TAIWAN LIPOSOME/S's stock symbol?

TAIWAN LIPOSOME/S trades on the NASDAQ under the ticker symbol "TLC."

How do I buy shares of TAIWAN LIPOSOME/S?

Shares of TLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TAIWAN LIPOSOME/S's stock price today?

One share of TLC stock can currently be purchased for approximately $4.91.

How big of a company is TAIWAN LIPOSOME/S?

TAIWAN LIPOSOME/S has a market capitalization of $182.16 million and generates $6.99 million in revenue each year. The company earns $-27,000,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

What is TAIWAN LIPOSOME/S's official website?

The official website for TAIWAN LIPOSOME/S is www.tlcbio.com.

How can I contact TAIWAN LIPOSOME/S?

TAIWAN LIPOSOME/S's mailing address is 11TH FLOOR-1 YUANQU STREET NANGANG DISTRICT, TAIPEI CITY F5, 11503. The company can be reached via phone at 886-2-2655-7377 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.